This video provides highlights from the second half of the Invivoscribe corporate workshop, MRD Solutions for the Studies of Hematologic Malignancies, at AMP 2016 in Charlotte, North Carolina, USA. The speaker Dr. Brad Patay, the Chief Medical Officer at Invivoscribe, discusses the value of minimal residual disease (MRD) testing in acute myeloid leukemia patients and the FLT3 ITD MRD next-generation sequencing testing service offered by LabPMM, Invivoscribe’s clinical laboratories.